Neurology® Podcast

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Hans Dieter Katzberg about the AAN guidelines on treatment for muscle cramps. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about coat hanger sing in multiple sclerosis atrophy. In the next part of the podcast Dr. Beau Bruce interviews Dr. Robert Naismith for our Lesson of the Week about natalizumab (Tysabri). The participants had nothing to disclose except Drs. Burns and Katzberg. Dr. Burns receives a stipend as Podcast Editor for Neurology®, performs EMG studies in his neuromuscular practice (30% effort), and received compensation for a presentation on MG-QOL15, given to study investigators of eculizumab in myasthenia gravis.Dr. Katzberg has received funding for travel from the Muscular Dystrophy Association.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Benjamin Atkinson interviews Dr. Thanh Phan about his paper on hypoxic coma: A meta-analysis. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about distinguishing dystonic tremor from essential tremor. In the next part of the podcast Dr. Julian Bragg interviews Dr. Miguel Hernán for our Lesson of the Week about bias. The participants had nothing to disclosure.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. John Ly about his paper on cerebral amyloid angiopathy related hemorrhage. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about psychogenic non-epileptic seizures. In the next part of the podcast, Dr. Ted Burns interviews Dr Dan Larriviere for our Lesson of the week toolbox about principles of bioethics: respect of autonomy. The participants had nothing to disclosure except for Drs. Kissela, Larriviere and Burns.Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke.Dr. Burns receives a stipend as Podcast Editor for Neurology®, performs EMG studies in his neuromuscular practice (30% effort), and received compensation for a presentation on MG-QOL15, given to study investigators of eculizumab in myasthenia gravis.Dr. Larriviere has received honoraria for serving on the American Association for the Advancement of Science Faculty and has received an unrestricted educational grant from Allergan, Inc.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Quigg interviews Dr. Rainer Surges and Prof. Matthew Walker about their paper on generalized seizures. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about HSV-1 encephalitis and falsely negative PCR. In the next part of the podcast is Dr. Alberto Espay interviews Dr. Curt LaFrance for our Lesson of the week toolbox about psychogenic non-epileptic seizures. The participants had nothing to disclosure except for Prof. Walker, Drs. Surges and Espay. Dr. Surges received research support from Deutsche Forschungsgemeinschaft.Prof. Walker serves on scientific advisory boards for GlaxoSmithKline, Eisai Inc., UCB, and Sierra Neuro; has received travel expenses and honoraria for lectures or educational activities not funded by industry; serves as an Associate Editor of Epilepsia and Therapeutic Advances in Neurological Disorders and on the editorial boards of The Open Neurology Journal, Expert Opinion on Emerging Drugs, and Metabolic Brain Disease; receives royalties from publishing Understanding Epilepsy (BMA Family Doctor books, 1995); has received speaker honoraria from Eisai Inc. and UCB; serves as a consultant to Sierra Neuro; estimates that 20% of his clinical effort is on Video-EEG telemetry; and has received/receives research support from the Medical Research Council [G0400136 (PI), G0802158 (Co-I), G0701050 (Co-I), and G069336 (Co-I)], the European Community, Wellcome Trust, and Epilepsy Research UK.Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

1. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement. 2. [What's Trending]: On tau protein and Alzheimer dementia symptoms. In the first segment, Dr. Jason Crowell talks with Dr. James Russell about his paper on brain death, the determination of brain death, and member guidance for brain death accommodation requests. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Matthew Brier on tau protein and Alzheimer dementia symptoms.DISCLOSURES: Dr. Jason Crowell reports no disclosures. Dr. James Russell has served on Scientific Advisory Boards for Cytokinetics - Data Monitoring Board PROTOCOL CY 5022 A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE- RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). Dr. James Russell received travel funding from 1) Non-profit - Mexican Academy of Neurology - Funded travel and lodging to speak at Annual Meeting Nov 2018 - no honorarium (2) Non-profit - ALS Association - funded travel and lodging to do site visit for ALSA certification of UVA ALS Clinic. Dr. James Russell has publishing royalties from (1) Neuromuscular Disorders, McGraw-Hill, 2nd edition published 2015, with subsequent royalities 2) Honorarium for published article in Continuum: Approach to peripheral neuropathy. Continuum: Peripheral Nervous System Disorders. Fall 2017. Dr. James Russell has done consultancies with compensation for market research interviews regarding ALS therapeutics and is currently being compensated for expert opinion in two medical legal cases, one in support of the defendant and one in support of the plaintiff. Dr. Matthew Brier has received funding for Biogen, travel and accommodation and received research support for Medical Scientist Training Program Grant to WUSTL (5T32GM007200-37.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Shanna Patterson interviews Dr. Mauricio Delgado about his AAN guidelines on children and adolescents with cerebral palsy. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about triple-H sign in anterior choroidal artery infarction. The next part of the podcast is Dr. Alberto Espay interviews Dr. Joanna Jen for our Lesson of the week toolbox about benign paroxysmal positional vertigo vs. posterior circulation stroke. The participants had nothing to disclosure except Drs. Delgado and Espay. Dr. Delgado serves on the editorial board of Developmental Medicine and Child Neurology; has received research support from Abbott, Sciele Pharma, Inc., UCB, Allergan, Inc., the Hurst Foundation, the United Cerebral Palsy Research & Educational Foundation, the Linda and Don Carter Foundation, and the Crowley Carter Foundation; and estimates 50% of his clinical effort is spent on assessment and management of motor disorders of childhood, which includes treating children with cerebral palsy with oral antispasticity medications, ITB, and botulinum toxin injections.Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Valerie Voon about her paper on conversion disorder. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about checklist for using intravenous phenytoin. The next part of the podcast is the second portion to an interview by Dr. Beau Bruce talking with Dr. Stewart Teppert about triptans. The participants had nothing to disclosure except Dr. Voon. Dr. Voon serves on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of Movement Disorders; and was supported by an intramural National Institute of Neurological Disorders and Stroke fellowship.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Richard Dubinsky about his paper on transcutaneous electric nerve stimulation. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about neuroacanthocytosis can mimic Huntington disease. The next part of the podcast is excerpts from an AANEM interview with Dr. Ray Adams along with a brief introduction from Dr. Ted Burns. Theres a book review about Dr. Ray Adams in this weeks issue of Neurology. Please be sure to check out the review of the book, which is titled: Raymond Adams. A life of mind and muscle by Dr. Peter J. Koehler. The participants had nothing to disclosure except Dr. Dubinsky. Dr. Dubinsky serves on a scientific advisory board and speakers bureau for Allergan, Inc.; receives honoraria from BrioMed; receives research support from Allergan, Inc., Merz Pharmaceuticals GmbH, and the NIH [NHGRI/NINDS #1R01HG02449-01 (Site Investigator); NIAM/NINDS #R01NS052592 (Site Investigator), NIAM/NINDS #R01NS052619-01 (Site Investigator), NIAM/NINDS #R01NS052592-01 (Site Investigator), NCCAM #2007P000827 (Site Investigator), NCCAM #UO1AT000613 (Site Investigator)]; and his spouse owns stock in Abbott.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Juliana Lockman interview Dr. Roderick Duncan about his paper on psychogenic non epileptic attacks. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about rosary-like calcifications in carotid stenosis. The next part of the podcast is Dr. Michael Benatar interviews Dr. Chris Coffey for our Lesson of the week about non-inferiority trials. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclosure except Dr. Duncan. Dr. Duncan has received speaker honoraria and funding for travel from UCB.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interview Dr. Stephen Salloway about his paper on using bapineuzumab in mild to moderate Alzheimer disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Heidenhain variant of Creutzfeldt Jakob disease. The podcast concludes where Dr. Beau Bruce interviews Dr. Brian Weinshenker for the Lesson of the Week (disease of the month) on triptans. The participants had nothing to disclose except Drs. Burns & Salloway. Dr. Burns serves on the Neurology Podcast Committee.Dr. Salloway serves on scientific advisory boards for Myriad Genetics, Inc, Elan Corporation, Sanofi-aventis, Eisai Inc., and Pfizer; serves on the editorial board of the Journal of Neuropsychiatry and Clinical Neurosciences; receives royalties from American Psychiatric Press Inc and Humana Press; received speaker honoraria from Eisai Inc., Pfizer, Novartis, Forest Laboratories, Inc. and Elan Corporation; serves as a consultant to Merck Serono and Medivation-data safety committee; receives research support from Elan Corporation, Wyeth, Bristol-Myers Squibb, Alzheimers Disease Neuroimaging Initiative, Dominantly Inherited Alzheimers Network, Aging Brain: DTI, Subcortical Ischemia and Behavior and NIH [NIA 1 R03 AGO23916-01A1]; receives funding from The Norman and Rosalie Fain Family Foundation.